Epizyme, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2007)
Status: Acquired by Ipsen (2022)

Organization Overview

First Clinical Trial
2012
NCT01684150
First Marketed Drug
2020
tazemetostat (Tazverik)
First NDA Approval
2020
tazemetostat (Tazverik)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Epizyme, Inc. | EPIZYME INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Medullary (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Chordoma (Phase 2)

Hematologic Neoplasms (Phase 1)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Liver Diseases (Phase 1)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Mesothelioma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Prostatic Neoplasms (Phase 1)

Rhabdoid Tumor (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Synovial (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 33
  • # of Trial APIs: 30